Search Results - "Oyajobi, Babatunde O."

Transcriptional regulation of BMP2 expression by the PTH-CREB signaling pathway in osteoblasts by Zhang, Rongrong, Edwards, James R, Ko, Seon-Yle, Dong, Shanshan, Liu, Hongbin, Oyajobi, Babatunde O, Papasian, Christopher, Deng, Hong-Wen, Zhao, Ming

“…Intermittent application of parathyroid hormone (PTH) has well established anabolic effects on bone mass in rodents and humans. Although transcriptional…”
Get full text

Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo by Edwards, Claire M., Edwards, James R., Lwin, Seint T., Esparza, Javier, Oyajobi, Babatunde O., McCluskey, Brandon, Munoz, Steven, Grubbs, Barry, Mundy, Gregory R.

“…There is increasing evidence to suggest that the Wnt signaling pathway plays a critical role in the pathogenesis of myeloma bone disease. In the present study,…”
Get full text

CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease by Dairaghi, Daniel J., Oyajobi, Babatunde O., Gupta, Anjana, McCluskey, Brandon, Miao, Shichang, Powers, Jay P., Seitz, Lisa C., Wang, Yu, Zeng, Yibin, Zhang, Penglie, Schall, Thomas J., Jaen, Juan C.

“…The chemokine CCL3/MIP-1α is a risk factor in the outcome of multiple myeloma (MM), particularly in the development of osteolytic bone disease. This chemokine,…”
Get full text

The Zinc Finger Transcription Factor Gli2 Mediates Bone Morphogenetic Protein 2 Expression in Osteoblasts in Response to Hedgehog Signaling by Zhao, Ming, Qiao, Mei, Harris, Stephen E., Chen, Di, Oyajobi, Babatunde O., Mundy, Gregory R.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Synthesis of a Bone-Targeted Bortezomib with In Vivo Anti-Myeloma Effects in Mice by Wang, Hua, Xiao, Lifeng, Tao, Jianguo, Srinivasan, Venkat, Boyce, Brendan F, Ebetino, Frank H, Oyajobi, Babatunde O, Boeckman, Jr, Robert K, Xing, Lianping

“…Multiple myeloma (MM) is the most common cancer affecting the bone and bone marrow and remains incurable for most patients; novel therapies are therefore…”
Get full text

The hedgehog signaling molecule Gli2 induces parathyroid hormone-related peptide expression and osteolysis in metastatic human breast cancer cells by STERLING, Julie A, OYAJOBI, Babatunde O, GRUBBS, Barry, PADALECKI, Susan S, MUNOZ, Steve A, GUPTA, Anjana, STORY, Beryl, MING ZHAO, MUNDY, Gregory R

“…Parathyroid hormone-related peptide (PTHrP) is a major factor involved in tumor-induced osteolysis caused by breast cancers that have metastasized to bone…”
Get full text

Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease by Oyajobi, Babatunde O., Garrett, I. Ross, Gupta, Anjana, Flores, Alda, Esparza, Javier, Muñoz, Steve, Zhao, Ming, Mundy, Gregory R.

“…Summary Impaired bone formation contributes to the lack of bone healing in multiple myeloma and there is a need for agents with bone anabolic properties to…”
Get full text

Smurf1 Inhibits Osteoblast Differentiation and Bone Formation in Vitro and in Vivo by Zhao, Ming, Qiao, Mei, Harris, Stephen E., Oyajobi, Babatunde O., Mundy, Gregory R., Chen, Di

“…Bone morphogenetic proteins (BMPs) are required for normal postnatal bone formation and osteoblast differentiation. There is evidence from recent studies that…”
Get full text

Therapeutic Antitumor Efficacy of Anti-CD137 Agonistic Monoclonal Antibody in Mouse Models of Myeloma by MURILLO, Oihana, ARINA, Ainhoa, SOLANO, Sarai, PEREZ-GRACIA, José L, OYAJOBI, Babatunde O, MELERO, Ignacio, HERVAS-STUBBS, Sandra, GUPTA, Anjana, MCCLUSKEY, Brandon, DUBROT, Juan, PALAZON, Asis, AZPILIKUETA, Arantza, OCHOA, Maria C, ALFARO, Carlos

“…Purpose: Eradication of post-treatment residual myeloma cells is needed to prevent relapses, and immunostimulatory monoclonal antibodies (mAb) such as…”
Get full text

Inhibition of Microtubule Assembly in Osteoblasts Stimulates Bone Morphogenetic Protein 2 Expression and Bone Formation through Transcription Factor Gli2 by Zhao, Ming, Ko, Seon-Yle, Liu, Jin-Hua, Chen, Di, Zhang, Jianghong, Wang, Baolin, Harris, Stephen E., Oyajobi, Babatunde O., Mundy, Gregory R.

“…Article Usage Stats Services MCB Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts by Zhang, Rongrong, Oyajobi, Babatunde O, Harris, Stephen E, Chen, Di, Tsao, Christopher, Deng, Hong-Wen, Zhao, Ming

“…Abstract The BMP and Wnt/β-catenin signaling pathways cooperatively regulate osteoblast differentiation and bone formation. Although BMP signaling regulates…”
Get full text

Detection of myeloma in skeleton of mice by whole-body optical fluorescence imaging by Oyajobi, Babatunde O, Muñoz, Steve, Kakonen, Rami, Williams, Paul J, Gupta, Anjana, Wideman, Christi L, Story, Beryl, Grubbs, Barry, Armstrong, Allison, Dougall, William C, Garrett, I Ross, Mundy, Gregory R

“…Development of new therapies for myeloma has been hindered by the lack of suitable preclinical animal models of the disease in which widespread tumor foci in…”
Get full text

Myeloma cells exhibit an increase in proteasome activity and an enhanced response to proteasome inhibition in the bone marrow microenvironment in vivo by Edwards, Claire M., Lwin, Seint T., Fowler, Jessica A., Oyajobi, Babatunde O., Zhuang, Junling, Bates, Andreia L., Mundy, Gregory R.

“…The proteasome inhibitor bortezomib has a striking clinical benefit in patients with multiple myeloma. It is unknown whether the bone marrow microenvironment…”
Get full text

A niche-dependent myeloid transcriptome signature defines dormant myeloma cells by Khoo, Weng Hua, Ledergor, Guy, Weiner, Assaf, Roden, Daniel L., Terry, Rachael L., McDonald, Michelle M., Chai, Ryan C., De Veirman, Kim, Owen, Katie L., Opperman, Khatora S., Vandyke, Kate, Clark, Justine R., Seckinger, Anja, Kovacic, Natasa, Nguyen, Akira, Mohanty, Sindhu T., Pettitt, Jessica A., Xiao, Ya, Corr, Alexander P., Seeliger, Christine, Novotny, Mark, Lasken, Roger S., Nguyen, Tuan V., Oyajobi, Babatunde O., Aftab, Dana, Swarbrick, Alexander, Parker, Belinda, Hewett, Duncan R., Hose, Dirk, Vanderkerken, Karin, Zannettino, Andrew C.W., Amit, Ido, Phan, Tri Giang, Croucher, Peter I.

“…The era of targeted therapies has seen significant improvements in depth of response, progression-free survival, and overall survival for patients with…”
Get full text

Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma by McDonald, Michelle M., Reagan, Michaela R., Youlten, Scott E., Mohanty, Sindhu T., Seckinger, Anja, Terry, Rachael L., Pettitt, Jessica A., Simic, Marija K., Cheng, Tegan L., Morse, Alyson, Le, Lawrence M.T., Abi-Hanna, David, Kramer, Ina, Falank, Carolyne, Fairfield, Heather, Ghobrial, Irene M., Baldock, Paul A., Little, David G., Kneissel, Michaela, Vanderkerken, Karin, Bassett, J.H.Duncan, Williams, Graham R., Oyajobi, Babatunde O., Hose, Dirk, Phan, Tri G., Croucher, Peter I.

“…Multiple myeloma (MM) is a plasma cell cancer that develops in the skeleton causing profound bone destruction and fractures. The bone disease is mediated by…”
Get full text

Combined treatment with a transforming growth factor beta inhibitor (1D11) and bortezomib improves bone architecture in a mouse model of myeloma-induced bone disease by Nyman, Jeffry S, Merkel, Alyssa R, Uppuganti, Sasidhar, Nayak, Bijaya, Rowland, Barbara, Makowski, Alexander J, Oyajobi, Babatunde O, Sterling, Julie A

“…Abstract Multiple myeloma (MM) patients frequently develop tumor-induced bone destruction, yet no therapy completely eliminates the tumor or fully reverses…”
Get full text

TGF-β Promotion of Gli2-Induced Expression of Parathyroid Hormone-Related Protein, an Important Osteolytic Factor in Bone Metastasis, Is Independent of Canonical Hedgehog Signaling by JOHNSON, Rachelle W, NGUYEN, Mai P, PADALECKI, Susan S, GRUBBS, Barry G, MERKEL, Alyssa R, OYAJOBI, Babatunde O, MATRISIAN, Lynn M, MUNDY, Gregory R, STERLING, Julie A

“…Breast cancer frequently metastasizes to bone, in which tumor cells receive signals from the bone marrow microenvironment. One relevant factor is TGF-β, which…”
Get full text

Zerumbone Abolishes RANKL-Induced NF-κB Activation, Inhibits Osteoclastogenesis, and Suppresses Human Breast Cancer―Induced Bone Loss in Athymic Nude Mice by SUNG, Bokyung, MURAKAMI, Akira, OYAJOBI, Babatunde O, AGGARWAL, Bharat B

“…Receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL) has emerged as a major mediator of bone resorption, commonly associated with cancer and other…”
Get full text

Multiple myeloma/hypercalcemia by Oyajobi, Babatunde O

“…Multiple myeloma, a cancer of plasma cells, is associated with excessive tumor-induced, osteoclast-mediated bone destruction. Hypercalcemia remains the most…”
Get full text

Oxidatively modified low‐density lipoproteins are potential mediators of proteasome inhibitor resistance in multiple myeloma by Polusani, Srikanth R., Cortez, Valerie, Esparza, Javier, Nguyen, Huynh Nga, Fan, Hongxin, Velagaleti, Gopalrao V. N., Butler, Matthew J., Kinney, Marsha C., Oyajobi, Babatunde O., Habib, Samy L., Asmis, Reto, Medina, Edward A.

“…Proteasome inhibitor (PI) therapy has improved the survival of multiple myeloma (MM) patients. However, inevitably, primary or acquired resistance to PIs leads…”
Get full text